Atlas Trials

Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma

Clinical trial NCT03342300 · WITHDRAWN

Trial details

NCT number
NCT03342300
Sponsor
Peking University People's Hospital
Status
WITHDRAWN
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Progression-free SurvivalOverall SurvivalToxicity
Start date
2017-11-06
Primary completion
2020-11-15
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.